John S. Bridgeman

1.7k total citations
36 papers, 1.2k citations indexed

About

John S. Bridgeman is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, John S. Bridgeman has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 25 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in John S. Bridgeman's work include CAR-T cell therapy research (23 papers), Immune Cell Function and Interaction (19 papers) and T-cell and B-cell Immunology (16 papers). John S. Bridgeman is often cited by papers focused on CAR-T cell therapy research (23 papers), Immune Cell Function and Interaction (19 papers) and T-cell and B-cell Immunology (16 papers). John S. Bridgeman collaborates with scholars based in United Kingdom, United States and Australia. John S. Bridgeman's co-authors include Robert E. Hawkins, David E. Gilham, David A. Price, Andrew K. Sewell, Mark Holland, Steve Bagley, David K. Cole, John J. Miles, Kristin Ladell and Andreas Hombach and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

John S. Bridgeman

36 papers receiving 1.1k citations

Peers

John S. Bridgeman
Benjamin M. Whitlock United States
Zsolt Sebestyén Netherlands
Raquel Gomez-Eerland Netherlands
Tingxi Guo Canada
Wolfgang Paster Austria
Yvonne Kew United States
Jessica Hartmann Germany
Valentin Voillet United States
Özcan Met Denmark
Benjamin M. Whitlock United States
John S. Bridgeman
Citations per year, relative to John S. Bridgeman John S. Bridgeman (= 1×) peers Benjamin M. Whitlock

Countries citing papers authored by John S. Bridgeman

Since Specialization
Citations

This map shows the geographic impact of John S. Bridgeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Bridgeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Bridgeman more than expected).

Fields of papers citing papers by John S. Bridgeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Bridgeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Bridgeman. The network helps show where John S. Bridgeman may publish in the future.

Co-authorship network of co-authors of John S. Bridgeman

This figure shows the co-authorship network connecting the top 25 collaborators of John S. Bridgeman. A scholar is included among the top collaborators of John S. Bridgeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John S. Bridgeman. John S. Bridgeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bridgeman, John S., Anne K. Wouters, Ben de Wet, et al.. (2023). High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs. Journal of Biological Chemistry. 299(8). 104981–104981. 5 indexed citations
3.
4.
Pillai, Manon, Yi‐Zhou Jiang, Paul Lorigan, et al.. (2022). Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.. PubMed. 12(8). 3967–3984. 7 indexed citations
5.
Clement, Mathew, James E. McLaren, Kristin Ladell, et al.. (2021). CD8 coreceptor-mediated focusing can reorder the agonist hierarchy of peptide ligands recognized via the T cell receptor. Proceedings of the National Academy of Sciences. 118(29). 8 indexed citations
6.
Hawkins, Robert E., Yizhou Jiang, Paul Lorigan, et al.. (2021). Abstract LB150: Clinical Feasibility and Treatment Outcomes with Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients with Advanced Cutaneous Melanoma. Cancer Research. 81(13_Supplement). LB150–LB150. 2 indexed citations
7.
8.
Spindler, Matthew, John S. Bridgeman, James Heather, et al.. (2020). Massively parallel interrogation and mining of natively paired human TCRαβ repertoires. Nature Biotechnology. 38(5). 609–619. 37 indexed citations
9.
Cole, David K., Anna Fuller, Garry Dolton, et al.. (2017). Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope. Frontiers in Immunology. 8. 1503–1503. 20 indexed citations
10.
Gilham, David E., John Anderson, John S. Bridgeman, et al.. (2015). Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015. Human Gene Therapy. 26(5). 276–285. 15 indexed citations
11.
Motozono, Chihiro, John S. Bridgeman, David A. Price, Andrew K. Sewell, & Takamasa Ueno. (2015). Clonotypically similar hybridαβT cell receptors can exhibit markedly different surface expression, antigen specificity and cross-reactivity. Clinical & Experimental Immunology. 180(3). 560–570. 2 indexed citations
12.
Berg, Hugo A. van den, Kristin Ladell, Kelly L. Miners, et al.. (2013). Cellular-Level Versus Receptor-Level Response Threshold Hierarchies in T-Cell Activation. Frontiers in Immunology. 4. 250–250. 19 indexed citations
13.
Nickolay, Lauren, et al.. (2012). Generation of human antigen-specific regulatory T cells by MHC-class I restricted T cell receptor gene transfer. Immunology. 137. 693–693. 1 indexed citations
14.
Bridgeman, John S., Andrew K. Sewell, John J. Miles, David A. Price, & David K. Cole. (2011). Structural and biophysical determinants of αβ T‐cell antigen recognition. Immunology. 135(1). 9–18. 93 indexed citations
15.
Holland, Mark, Fernanda Castro, Duncan L. Smith, et al.. (2011). RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood. 118(3). 638–649. 42 indexed citations
16.
Cheadle, Eleanor J., et al.. (2011). Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Therapy. 19(11). 1114–1120. 41 indexed citations
17.
18.
Bridgeman, John S., Robert E. Hawkins, Andreas Hombach, Hinrich Abken, & David E. Gilham. (2010). Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy. Current Gene Therapy. 10(2). 77–90. 84 indexed citations
19.
Bridgeman, John S., David E. Gilham, Robert E. Hawkins, & Eleanor J. Cheadle. (2009). The second cellular therapy of cancer symposium, 27–29 March 2009, Milan, Italy. Cancer Immunology Immunotherapy. 59(6). 971–974. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benjamin M. Whitlock Breakdown of academic impact, for papers by Zsolt Sebestyén Breakdown of academic impact, for papers by Raquel Gomez-Eerland Breakdown of academic impact, for papers by Tingxi Guo Breakdown of academic impact, for papers by Wolfgang Paster Breakdown of academic impact, for papers by Yvonne Kew Breakdown of academic impact, for papers by Jessica Hartmann Breakdown of academic impact, for papers by Valentin Voillet Breakdown of academic impact, for papers by Özcan Met
Rankless by CCL
2026